Literature DB >> 2969304

Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.

J L Au1, M G Wientjes, S L Bramer.   

Abstract

Uridine (UR) inhibits the metabolic activation of 5'-deoxy-5-fluorouridine (dFUR) to 5-fluorouracil (FU) by the intestinal pyrimidine nucleoside phosphorylases and could potentially reduce its intestinal toxicity. This study examined the effect of UR coadministration on the absorption and disposition of an oral dose of dFUR. Rats were given dFUR alone (500 mg kg-1) and dFUR (300 mg kg-1) plus UR (4.5 g kg-1) in a random crossover experiment. Simultaneous injection of a tracer dose of [6-3H]dFUR was used to asses the total body clearance (Cl) of dFUR. The absorption of UR was rapid and variable. The UR dose produced a maximal blood concentration of 80 micrograms/ml for UR and 100 micrograms/ml for its metabolite uracil (U). The absorption of dFUR was slower than UR, as indicated by its later time of maximal concentration. UR did not alter the Cl of dFUR, but reduced the absorption rate of dFUR from the gastrointestinal tract and significantly reduced the absolute oral bioavailability of dFUR from 55.2% to 33.4%. The effects of UR coadministration on the dFUR metabolite FU were opposite to those on dFUR; the FU availability was increased sixfold, and the elimination of FU was reduced. Based on the known competition between pyrimidine bases for their saturable metabolic enzymes, the increase in FU availability by UR coadministration was likely due to a competitive inhibition of FU metabolism by U. This study established the complex pharmacokinetic interactions between dFUR and UR and between their metabolites, which may be important in the modulation of dFUR activity by UR.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969304     DOI: 10.1007/bf00254172

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  Novel single-pass exchange of circulating uridine in rat liver.

Authors:  T Gasser; J D Moyer; R E Handschumacher
Journal:  Science       Date:  1981-08-14       Impact factor: 47.728

2.  Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

3.  Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs.

Authors:  J M Covey; J A Straw
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

4.  Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma.

Authors:  P Alberto; M Rozencweig; M Clavel; P Siegenthaler; F Cavalli; S Gundersen; U Bruntsch; J Renard; H Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Differential selectivity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia.

Authors:  J L Au; Y M Rustum; J Minowada; B I Srivastava
Journal:  Biochem Pharmacol       Date:  1983-02-01       Impact factor: 5.858

6.  Role of administration route in the therapeutic efficacy of doxifluridine.

Authors:  F Trave; L Canobbio; J L Au; Y M Rustum
Journal:  J Natl Cancer Inst       Date:  1987-03       Impact factor: 13.506

7.  Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.

Authors:  R Abele; P Alberto; R J Seematter; G Germano; R Heintz; W Bollag
Journal:  Cancer Treat Rep       Date:  1982-06

8.  Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.

Authors:  A Leyva; C J van Groeningen; I Kraal; H Gall; G J Peters; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

9.  Inhibition of intestinal pyrimidine nucleoside phosphorylases.

Authors:  M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

10.  Modulation of the effects of fluoropyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine.

Authors:  H R Hartmann; W Bollag
Journal:  Med Oncol Tumor Pharmacother       Date:  1986
View more
  2 in total

1.  Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.

Authors:  D S Martin; R L Stolfi; R C Sawyer
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.

Authors:  Y Sawai; K Yamaoka; T Nakagawa
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.